About this trial
End-stage renal disease patients needs a functional vascular access to receive hemodialysis and prolong their lives. Arteriovenous fistula (AVF) is priority consideration for hemodialysis, which is a connecting a superficial vein to a nearby artery and allowing this vein to enlarge and increase in internal diameter under arterial circulation. Unfortunately, 30-50% of fistulae fail to mature. Vascular calcification and stenosis were considered for early failure. The perivascular fat of artery can be predicted successful AVF maturation. However, Few previous studies have compared AVF maturation between perivascular the fat of cephalic vein or removal during the AVF surgery. This study evaluated whether the effect of AVF inflammation and preexisting vascular fibrosis is associated to perivascular the fat of cephalic vein. Investigators will also verify inflammation by analysis of blood and tissue samples, the association of pre-existing fibrosis, and the clinical correlation with AVF early failure.
This study will enroll patients with chronic kidney disease stage 5 and stage 6 who will need maintenance-hemodialysis (HD) from Nov 2021 to Dec 2022. Investigators will use the preoperative ultrasound assessment tool to confirm the feasibility of the arm vessels for the creation of a native AVF. As a prospective randomized controlled trial of perivascular fat preservation or removal during the AVF surgery, a study assistant will help the randomization and explain the informed consent to the patient . The subjects are randomly split into two groups: the experimental group will have the perivascular fat of the target cephalic vein preserved the control group will have the fat removed before the AVF anastomosis. The survey will enroll 100 adult patients and categorize them into groups according to each AVF maturation, JAS, or FTM (see definition below) by 3 - 12 after the surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age of 20 and older adult patients.
preoperatively clinical and ultrasound assessment of the arm vessels are visible for the creation of a native HDAVF that include:the augmented diameters of the veins is > 2.0 mm and the diameter of the radial artery is> 2.0 mm. Besides, there is no obvious stenosis of vessels in the forearm.
Disqualifiers
The patient refused to join the study
serious heart failure (Physicians identify insufficient cardiac output that may affect sacral blood flow development after surgery)
Unconsciousness
Bedridden for long time
Trial design
Parallel
Treatments tested in this trial
preserve
Procedure/Surgerypreserve the perivascular fat of the target cephalic vein
Treatment groups
Trial outcomes
Primary outcomes
The success by ultrasound parameters.
Investigators propose an objective ultrasound scoring system(A hemodialysis arteriovenous fistula maturity score based on the following three objective ultrasonic measurements). Higher scores indicating more mature. Give a summary score range from 0 to 9 points., and of which a total of score 4 or more is considered as HDAVF maturation.
Definition of delay maturation
The subject HDAVF is clinically un-feasible for use for HD within 3 months and/or the A hemodialysis arteriovenous fistula maturity score(AFMS) based on the following three objective ultrasonic measurements(0-9) is less than 4. within 3 months and/or the A hemodialysis arteriovenous fistula maturity score based on the following three objective ultrasonic measurements is less than 4(AVF maturity score based on the following three objective ultrasonic measurements. 0 to 9.).
Secondary outcomes
The subject HDAVF is clinically un-feasible for use for HD within 3 months and/or the A hemodialysis arteriovenous fistula maturity score(AFMS) based on the following three objective ultrasonic measurements(0-9) is less than 4.
infection, bleeding, stroke, MI, deep vein thrombosis,peripheral arterial occlusion disease, died
Sponsors and contacts
Click on the lead sponsor to view all of their trials.